Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
The press release provides key information on the total number of shares and voting rights of the Company as of August 31, 2020. As per the report, the total number of shares stands at 54,927,187, while the total gross voting rights amount to 54,927,187. The total net voting rights, after accounting for shares without voting rights, is 54,844,056. This information is in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies has announced major leadership changes effective October 2, 2020. CFO Ramzi Benamar and CCO Kevin Trapp will depart, while Sébastien Robitaille will assume the CFO role. Robitaille, with a tenure at DBV since 2015, brings extensive experience through various leadership positions, including Chief Transformation Officer. The company expresses gratitude for the outgoing executives' contributions, highlighting Benamar's role in strengthening the balance sheet and Trapp's development of a commercial strategy for Viaskin Peanut. DBV also noted a recent FDA Complete Response Letter regarding its Biologics License Application.
DBV Technologies, a clinical-stage biopharmaceutical company, announced participation in several investor conferences in September 2020, including:
- Citi’s 15th Annual BioPharma Virtual Conference on September 9-10.
- Goldman Sachs 10th Annual Biotech Symposium on September 11.
- H. C. Wainwright 22nd Annual Global Investment Conference from September 14-16, featuring a fireside chat by CEO Daniel Tassé on September 15 at 10:00 AM ET.
- Morgan Stanley 18th Annual Global Healthcare Conference from September 14-18, with Daniel Tassé speaking on September 16 at 8:45 AM ET.
Webcasts of these events will be available on DBV's website.
As of July 31, 2020, the company reports a total of 54,927,187 shares outstanding. The total number of voting rights amounts to 54,927,187 gross and 54,867,787 net, after excluding shares without voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers for market transparency.